Plain-English translation of NCT07534592 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are studying how , a new medication being developed by AstraZeneca, affects how your body processes two common cholesterol medications: and . The study will involve healthy volunteers taking these medications alone and then together with to see if the new medication changes how the cholesterol drugs are absorbed and cleared from the body.
Before this medication can be used safely with cholesterol drugs, doctors need to understand whether it changes how those medications work. This study helps ensure that people taking both medications together won't experience unexpected side effects or reduced effectiveness.
You would be in the study for approximately 15–16 weeks depending on which group you're assigned to. You'll visit the research center multiple times to take the study medication and cholesterol drugs in different combinations while researchers monitor how your body processes them. Blood samples will be taken regularly to measure medication levels in your bloodstream, and you'll have an initial screening visit and a follow-up visit after the treatment periods end.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
AstraZeneca
Collaborators
Parexel
Enrollment target
~48 participants
Started
April 2026
Primary completion
August 2026
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in June 2026.